Progress in Neuro-Psychopharmacology and Biological Psychiatry
April 20, 2024
Juliana Marino Maia, Bruna Stefane Alves De Oliveira, Luiz G.s. Branco et al.
11 citations
Psychedelics (serotonergic hallucinogens) are psychoactive substances that can alter perception and mood, and affect cognitive functions. These substances activate 5-HT2A receptors and may exert therapeutic effects. Some of the disorders for which psychedelic-assisted therapy have been studied include depression, addiction, anxiety and post-traumatic stress disorder. Despite the increasing...
Journal For International Medical Graduates
April 18, 2024
Sarosh Nawaz, Abdulaziz Mohammed Althwanay, B Esraa M. Aledani Mb Ch et al.
The impact of psychedelic treatment on patients suffering from psychiatric diseases like depression, anxiety, post-traumatic psychiatric disorder (PTSD), and existential distress related to cancer has become very intriguing to psychiatrists in the modern era. Serotonergic psychedelics include Lysergic acid diethylamide (LSD), psilocybin, mescaline, ayahuasca, and methylene-deoxy methamphetamine...
April 14, 2024
Vaibhav Tripathi, Ishaan Batta, Andre Zamani et al.
preprint
The default mode network (DMN) is intricately linked with processes such as self-referential thinking, episodic memory recall, self-projection, and understanding the mindset of others. Over recent years, there has been a surge in examining its functional connectivity, particularly its antagonistic relationship with frontoparietal networks (FPN) involved in top-down attention, executive...
Research, Society and Development
April 11, 2024
Jéssica de Sá Azevedo, Aline da Silva Guerra
1 citation
O transtorno do espectro autista é uma condição no neurodesenvolvimento que causa déficits na interação interpessoal e na comunicação do indivíduo, podendo levar ao desenvolvimento da ansiedade social. A inexistência de um tratamento farmacológico eficaz e com efeitos colaterais reduzidos, tem atraído a atenção dos pesquisadores para o tratamento com abordagens alternativas. O...
bioRxiv : the preprint server for biology
April 11, 2024
Ana Sofia Alberto-Silva, Selina Hemmer, Hailey A. Bock et al.
preprint
3,4-Methylenedioxymethamphetamine (MDMA, ' ecstasy' ) is re-emerging in clinical settings as a candidate for the treatment of specific psychiatric disorders (e.g. post-traumatic stress disorder) in combination with psychotherapy. MDMA is a psychoactive drug, typically regarded as an empathogen or entactogen, which leads to transporter-mediated monoamine release. Despite its therapeutic...
Journal of Psychedelic Studies
April 2, 2024
Sonia M. Brodie, Chelsea Stunden, Jay A. Olson et al.
AbstractBackground and aimsFirst responders such as firefighters and police officers often experience traumatic events as part of their work. As a result, they are more likely to have mental health issues such as post-traumatic stress disorder, depression, and anxiety compared to the general population. Psychedelic-assisted therapy has emerged as a promising avenue to alleviate these issues,...
Nervenheilkunde
April 1, 2024
Laura Bechtold, Dimitris Repantis
ZUSAMMENFASSUNGNeben den klassischen Psychedelika, z. B. Psilocybin, werden wieder vermehrt andere Substanzen wie 3,4-Methylendioxy-N-methylamphetamin (MDMA) erforscht. Das Entaktogen („innerlich berührend“) ist in den USA nur noch wenige Schritte von einer möglichen Zulassung zur Behandlung der posttraumatischen Belastungsstörung entfernt. Dieser Artikel soll einen Überblick über die Wirkung,...
Nervenheilkunde
April 1, 2024
Uwe Herwig
3 citations
ZUSAMMENFASSUNG Psychedelika stoßen in der Psychiatrie auf ein erneut zunehmendes fachliches und wissenschaftliches Interesse. Nach einer intensiveren Phase des Einsatzes im psychotherapeutischen Kontext Mitte des letzten Jahrhunderts kam die Forschung in dem Bereich nach gesetzlichen Verboten weitestgehend zum Erliegen. Erst seit wenigen Jahren wird das klinische Potenzial wieder mit modernen...
European Psychiatry
April 1, 2024
N. Kabir, B. Anderson, Lisa Bouchet et al.
1 citation
Introduction Growing clinical interest in psychedelic-assisted therapies has led to a second wave of research involving psilocybin, LSD, MDMA and other substances. Data suggests that these compounds have the potential to treat mental health conditions that are especially prevalent in older adults such as depression, anxiety, existential distress and post-traumatic stress disorder. Objectives...
Neuropsychopharmacology
April 1, 2024
Thomas J. Kelly, Emma M. Bonniwell, Lianwei Mu et al.
26 citations
Psychedelics such as psilocybin show great promise for the treatment of depression and PTSD, but their long duration of action poses practical limitations for patient access. 4-OH-DiPT is a fast-acting and shorter-lasting derivative of psilocybin. Here we characterized the pharmacological profile of 4-OH-DiPT and examined its impact on fear extinction learning as well as a potential mechanism...